Celonic
Crafting Biopharmaceuticals through Innovation and Expertise

Celonic, a contract development and manufacturing organisation’s (CDMO) story is one of dedication and partnership, built around a simple yet powerful idea—helping biopharmaceutical companies bring life-changing therapies to the people who need them. Whether it’s a small biotech startup working on a groundbreaking treatment or a larger biosimilar company refining an established drug, Celonic offers tailored support from the earliest stages of development all the way through to market supply.

At the heart of Celonic’s work is a genuine understanding of its clients. This isn’t just about delivering a service—it’s about listening to each company’s unique needs and challenges. Every interaction is a chance to make a difference, streamline processes and shorten timelines, ensuring that new treatments can reach patients faster and more effectively.

“It is an honor to be appointed CEO of the Celonic Group. I am energised to leverage the talent, expertise and passion of the entire Celonic organisation to meet and exceed our customer expectations and bring game-changing technologies to the market,” says Samanta Cimitan, CEO.

Celonic’s innovative platforms, like GS-CHOvolution and GEX—a proprietary cell line development platform—are a reflection of that drive. These technologies simplify and speed up the production of biologics, such as monoclonal antibodies, allowing companies to bring high-quality drugs to market quickly and affordably.

GS-CHOvolution, in particular, stands out for its ability to simplify the complex process of producing biologics like monoclonal antibodies and bispecifics. Using a gene-edited Chinese Hamster Ovary (CHO) expression system, this platform removes many of the bottlenecks that traditionally slow down drug development.

What sets it apart is its use of a glutamine synthetase (GS) knockout approach, a precise genetic modification that eliminates the need for antibiotic selection— saving time and ensuring regulatory compliance. Simplifying cell line development, GS-CHOvolution slashes timelines to under 12 months, relying on high-throughput automation and rigorous analytics to drive productivity and mitigate risk. The platform is designed for seamless scalability, enabling both small biotech startups and larger pharmaceutical companies to expand production without relying on glutamine supplementation, making it adaptable to their evolving needs.

The GEX platform brings its own unique strength to the table by supporting fully human glycosylation patterns. This capability is a game-changer in biopharmaceutical production, as it allows for the creation of proteins that are more compatible with the human body, enhancing both the safety and efficacy of the therapies developed. It’s not just about speed—it’s about creating biologics better suited for patient use, leading to more effective treatments with fewer complications.
CIOS_QUOTES_REPLACE]
Celonic’s use of single-use technology in both perfusion and fed-batch processes further enhances its ability to deliver on this promise. These methods boost productivity by increasing overall production yields and lowering costs, while also supporting sustainability efforts by reducing waste and energy consumption. The move away from traditional stainless-steel processes to single-use systems marks another step forward in making biomanufacturing more efficient, cost-effective and environmentally responsible.

The evolution of Celonic from a research-focused firm to a full-scale GMP manufacturing organisation reflects its dedication to advancing the biopharma industry. Offering fully integrated services, Celonic covers the entire spectrum of formulation development and fill-and-finish operations, ensuring a seamless and comprehensive production process.

The company is pushing the boundaries of drug development, turning once-distant possibilities into immediate realities. With a clear vision for the future, Celonic is not just advancing biopharma—it’s reshaping how life-saving treatments reach patients, delivering hope and health faster and more effectively than ever.